EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pregnancy- and perinatal-related adverse-event reporting patterns of antiseizure medications: FAERS screening with JADER and clinical evidence

Yinping Liu, Lingfang Dong, Yan Wang, Shujuan Zhao

Frontiers in Pharmacology · 18.11.2026 · 17

DOI: 10.3389/fphar.2026.2002623 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 18.11.2026. Verfasst von Yinping Liu und 3 weiteren Autor:innen. Die Arbeit nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pregnancy- and perinatal-related reporting signals for anti-seizure medications (ASMs) require assessment against other reporting sources and clinical studies.

Objective

The aim in this study was to assess selected ASM reporting hypotheses across US Food and Drug Administration Adverse Event Reporting System (FAERS), Japanese Adverse Drug Event Report database (JADER), and clinical studies and identify priorities for clinical investigation.

Methods

Deduplicated FAERS reports from 2004Q1–2026Q2 were screened. Eligibility required female sex, an epilepsy-related indication, and a suspect ASM: carbamazepine, lamotrigine, levetiracetam, phenobarbital, phenytoin, primidone, topiramate, or valproate. Maternal pregnancy exposure was not verified. Reporting odds ratios (RORs) compared indexed-ASM primary/secondary-suspect reports with other-target-ASM reports lacking indexed-suspect entries. Signals required at least three drug-outcome reports and a lower 95% confidence interval (CI) bound above 1. Three exploratory pairs and one valproate positive control underwent seven core FAERS sensitivity analyses, JADER analysis, and qualitative clinical evidence synthesis. Sensitivity analyses excluded any-role indexed-drug mentions from comparators and required drug-linked epilepsy indications.

Results

Among 42,290 eligible reports, 54 drug-preferred term signals yielded 27 clinical candidates after exclusions and grouping. Three exploratory pairs and one positive control underwent cross-source evaluation. Levetiracetam–preterm delivery (481 reports; ROR 2.68, 95% CI 2.24–3.21) retained its signal in all seven core analyses and under the comparator and indication restrictions. It was the only exploratory pair meeting the signal criteria in both databases. The JADER estimate was very imprecise, based on eight indexed-drug and one comparator outcome report (ROR 18.61, 95% CI 2.33–148.99). Available direct clinical estimates remained inconclusive. Levetiracetam–pregnancy loss and lamotrigine–cardiac congenital anomaly lacked consistent external corroboration. The valproate–central nervous system congenital anomaly positive control was supported by clinical studies, while FAERS findings were unstable and JADER reporting was sparse.

Conclusion

Levetiracetam–preterm delivery remains a reporting hypothesis with an unconfirmed clinical association. Cohorts comparing monotherapy regimens with verified pregnancy exposure are warranted. The other exploratory findings also remain hypotheses.

Zitieren

APA

Liu, Y., Dong, L., Wang, Y., & Zhao, S. (2026). Pregnancy- and perinatal-related adverse-event reporting patterns of antiseizure medications: FAERS screening with JADER and clinical evidence. Frontiers in Pharmacology, 17. https://doi.org/10.3389/fphar.2026.2002623

Vancouver

Liu Y, Dong L, Wang Y, Zhao S. Pregnancy- and perinatal-related adverse-event reporting patterns of antiseizure medications: FAERS screening with JADER and clinical evidence. Frontiers in Pharmacology. 2026;17. doi:10.3389/fphar.2026.2002623

BibTeX
@article{Liu2026,
  author = {Liu, Yinping and Dong, Lingfang and Wang, Yan and Zhao, Shujuan},
  title = {Pregnancy- and perinatal-related adverse-event reporting patterns of antiseizure medications: FAERS screening with JADER and clinical evidence},
  journal = {Frontiers in Pharmacology},
  year = {2026},
  volume = {17},
  doi = {10.3389/fphar.2026.2002623}
}
Kostenlos starten →